Tocagen Inc

Tocagen — Forte Biosciences — Investor Presentation (November 2020)

30 slides from Tocagen's investor presentation, Nov 10, 2020

  1. Slide 1: Forte Biosciences Corporate Presentation November 2020

    Exhibit 99.1 FORTE BIOSCIENCES TOPICAL LIVE BIOTHERAPEUTIC FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASE CORPORATE PRESENTATION NOVEMBER 2020Exhibit 99.1 FORTE BIOSCIENCES TOPICAL LIVE BIOTHERAPEUTIC FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASE CORPORATE PRESENTATION NOVEMBER 2020

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securitie

  3. Slide 3: Summary of Forte Biosciences: FB-401

    SUMMARY OF FORTE BIOSCIENCES: FB-401 – POTENTIAL FIRST-IN-CLASS TOPICAL LIVE BIOTHERAPEUTIC FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASE ¡ Phase 2a trial in atopic dermatitis completed including pediatrics 3 years and older, FB-401 was well LATE-STAGE tolerated and demonstrated clinical improvemen

  4. Slide 4: Forte Biosciences: Overview of FB-401

    FORTE BIOSCIENCES: OVERVIEW OF FB-401 ¡ FB-401 drug product consists of 3 therapeutic bacterial strains of commensal gram negative R. mucosa specifically selected based on screening for impact on inflammatory skin disease parameters ¡ Topical application of the specifically selected therapeutic bact

  5. Slide 5: Experienced Management and Advisory Teams

    EXPERIENCED MANAGEMENT AND ADVISORY TEAMS ¡ Forte BioSciences team has extensive experience in microbial manufacturing, quality, regulatory and clinical development in dermatology Paul Wagner, Ph.D. – CEO Dan Burge, MD – Head of Clinical Development Eric Emery – Head of Downstream Manufacturing Tony

  6. Slide 6: Atopic Dermatitis

    ATOPIC DERMATITIS ¡ Atopic dermatitis (AD) is characterized by itching, a scaly rash, dry skin, and cutaneous sensitization to allergens. The underlying pathology of AD consists of a triad of defective skin barrier function, susceptibility to Staphylococcus aureus skin infection, and immune imbalanc

  7. Slide 7: Skin Microbiome

    SKIN MICROBIOME The skin is a complex barrier organ characterized by symbiotic relationship between microbial communities and host tissue via complex signals provided by the innate and the adaptive immune systems Exposure to various endogenous and exogenous factors impact the system balance potentia

  8. Slide 8: Skin Microbiome Differences in Atopic Dermatitis

    SKIN MICROBIOME DIFFERENCES IN ATOPIC DERMATITIS Genetic-based microbiome identification revealed significant differences in the Gram-negative skin biome between atopic dermatitis (AD) patients and healthy controls (HV) NIH (Myles et. al.) identified substantial differences in the gram-negative micr

  9. Slide 9: Mechanism of FB-401

    MECHANISM OF FB-401 Extensive preclinical work by Forte in collaboration with NIH, investigating the activity of FB-401 has demonstrated: 1) FB-401 activates tissue repair and anti-inflammation pathways in keratinocytes, dendritic cells and fibroblasts 1) Gene sequencing of the FB-401 strains and mR

  10. Slide 10: Multiplex Gene Pathway Analysis: FB-401 Activates Tissue Repair Pathways

    MULTIPLEX GENE PATHWAY ANALYSIS (RNASEQ): FB-401 ACTIVATES TISSUE REPAIR/ANTI-INFLAMMATION PATHWAYS Gene FB ESC KC DC GPRIN3 2.76 Fibroblast, keratinocyte, embryonic stem cell and dendritic cell demonstrate TLR5 2.30 LY6D 1.99 tissue repair pathway activation following exposure to FB-401 including T

  11. Slide 11: Scratch Models Confirm Tissue Repair Through TLR5 Pathway Activation

    FIBROBLAST AND KERATINOCYTE SCRATCH MODELS CONFIRM TISSUE REPAIR THROUGH TLR5 PATHWAY ACTIVATION BY FB-401 Scratch model for Blocking TLR5 both keratinocytes (anti-TLR5 and fibroblasts antibody) demonstrates prevents tissue tissue repair by repair by FB-401 CONFIDENTIAL 11 PBS RmHV FB-401 FB Coverag

  12. Slide 12: TNFR Knock Out Mouse Models Confirm Dependence on TNFR Signaling

    TNFR KNOCK OUT MOUSE MODELS CONFIRMS RESPONSE TO FB- 401 IS DEPENDENT ON TNFR SIGNALING • TNFR wild type mice demonstrate atopic CONFIDENTIAL 12 dermatitis activity of FB-401 • TNFR knockout inhibits FB-401 activity Myles IA et al. Science Translational Medicine. 2020; 12TNFR KNOCK OUT MOUSE MODELS

  13. Slide 13: CXCR2 Knock Out Mouse Model Shows Dependence on IL-8 Signaling

    CXCR2 KNOCK OUT MOUSE MODEL DEMONSTRATES RESPONSE TO FB-401 IS DEPENDENT ON IL-8 SIGNALING CONFIDENTIAL 13 • CXCR2 wild type mice demonstrate atopic dermatitis activity of FB-401 • CXCR2 knockout inhibits FB-401 activityCXCR2 KNOCK OUT MOUSE MODEL DEMONSTRATES RESPONSE TO FB-401 IS DEPENDENT ON IL-8

  14. Slide 14: Phase 2a First Human Study of FB-401

    PHASE 2A FIRST HUMAN STUDY OF FB-401 - CUTANEOUS LIVE BIOTHERAPEUTIC FOR THE TREATMENT OF ATOPIC DERMATITIS Drug product: FB-401 (3 specifically selected therapeutic R. mucosa strains) lyophilized and reconstituted with sterile water in single-use, self-administered spray Design: Phase 1/2a enrolled

  15. Slide 15: Cohort Completed Treatment of Adults with AD

    COHORT 1 COMPLETED TREATMENT OF 10 ADULTS WITH AD Ten adult AD patients ages 18 years and older were treated in 2-week intervals 3 4 5 with 10 , 10 , and then 10 CFU of R mucosa twice per week (BIW) for a total of 6 weeks 15COHORT 1 COMPLETED TREATMENT OF 10 ADULTS WITH AD Ten adult AD patients ages

  16. Slide 16: Statistically Significant, Dose-Dependent Improvements in Adult Cohort

    STATISTICALLY SIGNIFICANT, DOSE-DEPENDENT IMPROVEMENTS OBSERVED IN ADULT COHORT OF PHASE 1/2a STUDY Only treated areas responded. No AD lesions that were untreated resolved over the course of the study Results from Cohort 1 indicate that six patients responded (60%) with mean improvement of 85%, one

  17. Slide 17: Cohort 2: FB-401 Treatment of Children with AD

    COHORT 2: FB-401 TREATMENT OF 20 CHILDREN WITH AD 20 pediatric/adolescent patients with active AD: ¡ First 5, ages 7-17 ¡ Remainder, ages 3-17 ¡ Baseline SCORAD >10 Pediatric Cohort Treatment Period Design: ¡ Treat AD-involved skin with FB-401 3 ¡ 10 CFU BIW for 4 weeks 4 ¡ 10 CFU BIW for 4 weeks 5

  18. Slide 18: Pediatric Patient Data Shows Significant Activity

    PEDIATRIC PATIENT DATA SHOWS SIGNIFICANT ACTIVITY – TREATMENT THROUGH W16, FOLLOW UP 6 M AFTER TREATMENT COMPLETION Dotted lines are data from patients that went direct to 10^5 Solid lines are dose escalation patients * p<0.05 ** P<0.01 Average Response *** p<0.001 Ave **** p<0.0001 baseline N SCORA

  19. Slide 19: Pruritus (Itch) Significantly Improved Over Course of Therapy

    PRURITIS (ITCH) SIGNIFICANTLY IMPROVED OVER COURSE OF THERAPY Part 2A Part 2B Total Pruritus Measures N=15 N=5 N=20 Mean baseline pruritus score 6.4 7.1 6.6 Mean Week 16 pruritus score 2.3 3.4 2.6 Mean % improvement 59.7% 51.0% 57.6% 19 CONFIDENTIAL Myles IA et al. Science Translational Medicine. 20

  20. Slide 20: Pediatric Patient EASI Efficacy Data Shows Significant Activity

    PEDIATRIC PATIENT EASI EFFICACY DATA SHOWS SIGNIFICANT ACTIVITY Average Response Ave baseline N EASI Responders % All Responders EASI-50 20 7.8 18 90.0% 76.8% 83.6% Ave baseline N EASI Responders % EASI-75 20 7.8 14 70.0% • Dotted lines are data from patients that went Ave baseline direct to 10^5 N

  21. Slide 21: Pediatric Efficacy Data Across Disease Severity

    PEDIATRIC PATIENT EFFICACY DATA SHOWS SIGNIFICANT ACTIVITY ACROSS DISEASE SEVERITY Mild Disease Moderate/Severe Disease Trial Protocol Total EASI=<7 at baseline EASI>=7 at baseline EASI =>5 at baseline N=11 N=9 N=14 N=20 EASI 50 81.8% (9/11) 100% (9/9) 100% (14/14) 90% (18/20) EASI 75 54.5% (6/11) 8

  22. Slide 22: Treatment with FB-401 Demonstrates Significant Improvement

    TREATMENT WITH FB-401 DEMONSTRATES SIGNIFICANT IMPROVEMENT Myles et al, JCI Insight, 2018;3(9):e120608 22TREATMENT WITH FB-401 DEMONSTRATES SIGNIFICANT IMPROVEMENT Myles et al, JCI Insight, 2018;3(9):e120608 22

  23. Slide 23: Representative Image of Improvement Following Therapy

    REPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY Week 0 Week 16 23 CONFIDENTIAL Myles IA et al. Science Translational Medicine. 2020; 12REPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY Week 0 Week 16 23 CONFIDENTIAL Myles IA et al. Science Translational Medicine. 2020; 12

  24. Slide 24: Representative Image of Improvement Following Therapy

    REPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY Week 16 Week 0 24 CONFIDENTIALREPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY Week 16 Week 0 24 CONFIDENTIAL

  25. Slide 25: Representative Image of Improvement Following Therapy

    REPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY Week 0 Week 16 25 CONFIDENTIAL Myles IA et al. Science Translational Medicine. 2020; 12REPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY Week 0 Week 16 25 CONFIDENTIAL Myles IA et al. Science Translational Medicine. 2020; 12

  26. Slide 26: Representative Image of Improvement Following Therapy

    REPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY Week 0 Week 16 26 CONFIDENTIAL Myles IA et al. Science Translational Medicine. 2020; 12REPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY Week 0 Week 16 26 CONFIDENTIAL Myles IA et al. Science Translational Medicine. 2020; 12

  27. Slide 27: Representative Image of Improvement Following Therapy

    REPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY 27 CONFIDENTIALREPRESENTATIVE IMAGE OF IMPROVEMENT FOLLOWING THERAPY 27 CONFIDENTIAL

  28. Slide 28: Planned FB-401 Randomized Phase 2 Study

    PLANNED FB-401 RANDOMIZED PHASE 2 STUDY • Randomized, placebo-controlled, multi-center study • Includes children (2 years and older), adolescents and adults with mild to moderate atopic dermatitis • Approximately 124 subjects randomized 1:1 to receive FB-401 or placebo for 16 weeks • Endpoints inclu

  29. Slide 29: Intellectual Property Overview

    INTELLECTUAL PROPERTY OVERVIEW ¡ Exclusive license to NIH-owned patent family focused on treatment of AD with a consortia of gram negative bacteria from healthy donors ¡ Patent coverage through at least 2037 ¡ 7 US patents issued ¡ Entered in 10 Ex-US jurisdictions ¡ Europe, China, Canada, Japan, So

  30. Slide 30: Summary of Forte Biosciences: FB-401

    SUMMARY OF FORTE BIOSCIENCES: FB-401 – POTENTIAL FIRST-IN-CLASS TOPICAL LIVE BIOTHERAPEUTIC FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASE ¡ Phase 2a trial in atopic dermatitis completed including pediatrics 3 years and older, FB-401 was well LATE-STAGE tolerated and demonstrated clinical improvemen

Forte Biosciences — Investor Presentation (November 2020) on 6ix